Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Earnings Presentation (February 2018)
7 slides from Theravance Biopharma's earnings presentation, Feb 27, 2018
Slide 1: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that m
Slide 2: Advancing Multiple Opportunities for Value Creation: Programs in Focus in 2018
Advancing Multiple Opportunities for Value Creation Programs in Focus in 2018 TD-1473 Intestinally restricted JAK inhibitor TD-9855 NSRI in nOH Revefenacin (TD-4208) Nebulized LAMA in COPD Inhaled JAK inhibitor Serious respiratory diseases Trelegy Ellipta (FF/UMEC/VI) Single inhaler triple therapy I
Slide 3: TD-1473 in Development with Janssen Biotech
TD-1473 in Development with Janssen Biotech Shared belief in TD-1473 as a localized medicine with potential to transform the treatment landscape in inflammatory intestinal diseases Meaningful program enhancements for TD-1473 Accelerate clinical development; plan to advance UC and Crohn’s in parallel
Slide 4: TD-9855: Phase 2a Study in nOH in Progress, Results Expected 1H 2018
TD-9855: Phase 2a Study in nOH in Progress, Results Expected 1H 2018 Intention to seek expedited development path Purpose: Exploratory study to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance Understanding totality of symptoms encompasses tests of stand-up time, ortho
Slide 5: Revefenacin: NDA for Treatment of COPD in FDA Review, PDUFA Date November 13, 2018
NDA supported by Phase 3 efficacy and safety studies Primary endpoint achieved for both doses in both replicate efficacy studies Robust and sustained improvements in FEV1 Effective as monotherapy and as add-on to LABA or LABA/ICS Generally well tolerated Generally well tolerated in 12-month safety s
Slide 6: Focus in 2018
Advancing Multiple Opportunities for Value Creation Programs in Focus in 2018 TD-1473 Intestinally restricted JAK inhibitor TD-9855 NSRI in nOH Revefenacin (TD-4208) Nebulized LAMA in COPD Inhaled JAK inhibitor Serious respiratory diseases Trelegy Ellipta (FF/UMEC/VI) Single inhaler triple therapy I
Slide 7: Focus in 2018
Advancing Multiple Opportunities for Value Creation Programs in Focus in 2018 Managed by Theravance Biopharma: NSRI in nOH Revefenacin (TD-4208) Nebulized LAMA in COPD Velusetrag (TD-5108) SHT4 agonist in gastroparesis Inhaled JAK inhibitor Serious respiratory diseases Managed by GSK and Innoviva?:
Theravance Biopharma — Earnings Presentation (February 2018) on 6ix